FDA approves first eye drop for age-related vision loss

Investment Screen

continue

Thesis Direction

The FDA approval of the first eye drop for age-related vision loss signals a potential shift from invasive procedures to pharmaceutical management in ophthalmology. Pure-play or concentrated ophthalmic pharmaceutical companies that have the approved eye drop or competing products are likely to benefit from capturing new patient segments and recurring prescription revenues. The growth could also support specialized contract manufacturers of ophthalmic drugs if the eye drop gains rapid adoption.

Research Questions

• Which public company holds the commercial rights to the newly approved eye drop, and how material is this to their overall revenues?
• What is the addressable market size for age-related vision loss treatable by the approved product?
• Are there direct competitors in late-stage development for similar non-invasive treatments?
• Does the manufacturing of the new eye drop require specialized contract manufacturers, and who are the main suppliers?